Last reviewed · How we verify

NCT03100175

Strength and Aerobic Training in Elderly Lymphoma Patients During Chemotherapy and Its Impact on Treatment Outcomes, Patients Functioning and Biological Markers of Aging

Status unknown NA Last updated 4 April 2017
What this trial tests

NA trial testing physiotherapy in Strength Aerobic Training Elderly Lymphoma Sarcopenia Aging in 100 participants. Status unknown.

Timeline
1 May 2017
Primary endpoint
15 March 2019
15 March 2019

Quick facts

Lead sponsorRabin Medical Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment100
Start date1 May 2017
Primary completion15 March 2019
Estimated completion15 March 2019

Drugs / interventions tested

Conditions studied

Sponsor

Rabin Medical Center

Who can join

70 and older, any sex, with Strength Aerobic Training Elderly Lymphoma Sarcopenia Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Frailty, one of geriatric syndromes, is considered a major obstacle for recovery from physiological stress. Such stress is imposed on patients with cancer by virtue of the disease itself but even more so by the treatment. Moreover, malignancy and chemotherapy both cause accelerated loss of muscle mass, deconditioning, frailty and negative outcomes. Several studies showed that chemotherapy accelerates ageing. Muscle mass reserve was found to be a major predictor of outcomes in patients treated with chemotherapy. Recently, several studies suggest that active muscle strength training during chemotherapy may decrease side effects, improves the ability to deliver intended doses of treatment and may even affect oncological outcomes. In the proposed study we intend to assess the contribution of physical training to the well-being of chemotherapy treated older patients, assessed by molecular and physiological parameters. We intend to recruit lymphoma patients above age of 70 and prospectively and randomly assign them to the intervention group (strength, aerobic and balance training during the chemotherapy) and control group (standard care with no special emphasis on physical activity during the treatment). We will measure clinical outcomes such as treatment tolerance and effects as well as physiological outcomes (muscle strength and mass, elements activities of daily living) and laboratory markers of ageing such as DNA methylation, INK 4a expression, telomere length and serum levels of inteleukin 6, CRP among others. Our hypothesis is that physical training will improve patients' ability to complete the treatment with fewer side effects, will provide them with better daily functioning and better muscle strength/function. We also hypothesize that the ageing process, as shown by laboratory senescence markers, will be attenuated in the intervention group.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The effect of exercise-based interventions on health-related quality of life and physical function in older patients with cancer receiving medical antineoplastic treatments: a systematic review.
    Mikkelsen MK, Juhl CB, Lund CM, Jarden M, et al · · 2020 · cited 31× · PMID 33088348 · DOI 10.1186/s11556-020-00250-w

Verify or expand the search:

Other trials of physiotherapy

Trials testing the same drug.

Other Rabin Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03100175.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing